Table 1.
Baseline patient characteristics and genotype frequencies.
| Characteristics | All Treated Patients (n = 46) |
|---|---|
| Sex, n (%) | |
| Female | 18 (39%) |
| Male | 28 (61%) |
| Age (years), n (%) | |
| <55 | 14 (30%) |
| 55–65 | 12 (26%) |
| >65 | 20 (44%) |
| Metastatic site, n (%) | |
| 1 | 15 (33%) |
| 2 | 12 (26%) |
| >2 | 19 (41%) |
| VEGF rs2010963, n (%) | |
| G/G | 27 (58.7%) |
| G/C | 13 (28.3%) |
| C/C | 6 (13%) |
| VEGF rs1570360, n (%) | |
| G/G | 31 (67.4%) |
| G/A | 10 (21.7%) |
| A/A | 5 (10.9%) |
| VEGF rs699947, n (%) | |
| C/C | 34 (74%) |
| C/A | - |
| A/A | 12 (26%) |
| ICAM rs5498, n (%) | |
| A/A | 13 (28.3%) |
| A/G | 23 (50%) |
| G/G | 10 (21.7%) |
| ICAM rs1799969, n (%) | |
| G/G | 36 (78.3%) |
| G/A | 10 (21.7%) |
| A/A | - |
| KRAS rs61764370, n (%) | |
| Wild type | 12 (50%) |
| Mutant | 12 (50%) |
| NRAS rs11554290, n (%) | |
| Wild type | 9 (38.8%) |
| Mutant | 15 (61.2%) |
| BRAF rs113488022, n (%) | |
| Wild type | 20 (81.8%) |
| Mutant | 4 (18.2%) |